{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"153","value":"305"},{"groupId":"OG001","spread":"181","value":"343"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Maximum plasma drug concentration (Cmax) following a single dose of avapritinib","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEDIAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with a starting dose of 300 or 400 mg QD and available samples for PK","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Maximum Plasma Drug Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}